Wade Ackerman is a partner in Covington’s FDA Regulatory group and serves as co-lead of Covington’s Digital Health Initiative. Through his previous positions at the Senate HELP Committee and FDA’s Office of Chief Counsel, Ackerman has acquired unique insights into the evolving legal and regulatory landscape facing companies marketing FDA-regulated products.
While at the Senate HELP Committee, Ackerman served as Senior FDA Counsel to Ranking Member Patty Murray (D-WA) and, before that, Chairman Tom Harkin (D-IA). He was involved in all significant FDA legislative initiatives, oversight hearings, and other HELP Committee activities concerning the FDA, including the 21st Century Cures Act of 2016.
Before taking his Senate role, Ackerman worked for more than five years as Associate Chief Counsel within the FDA’s Office of Chief Counsel (OCC). At FDA, he served on the Agency’s negotiating team for PDUFA V. He later helped implement the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 and the Drug Quality and Security Act (DQSA) of 2013.
Ackerman received his JD from Harvard Law School in 2004, and his BS from the University of Illinois in 2001.